Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:Agios Pharmaceuticals: Results from the Phase 3 RISE UP study of Pyrukynd (mitapivat) in sickle cell anemia. An Food and Drug Administration decision to expand the use of Pyrukynd to treat thalassemia is also expected by Dec. 7. AdvertisementAkeso and Summit Therapeutics: A presentation of full Chinese results from the ivonescimab Phase 3 HARMONI-6 study in non-small cell lung cancer at the annual meeting of the European Society for Medical Oncology.